EyeGate to Develop Corticosteroid Solution for Retinal Disorders
EyeGate Pharma (Waltham, MA) announced that it
has received four federal grants totaling nearly $1 million
for programs that focus on the continued clinical development
of EGP-437, a corticosteroid solution administered by the EyeGate II delivery system. EyeGate II uses
iontophoresis, which occurs when an applied electr...